Nilesh Mehta, MD
Gastroenterology · New Hyde Park, NYNPI 1649436163
Payments from drug & device makers
What this record shows
This record is dominated by other: $12,692 of the $18,755 with a category attached, or 67.7%. Olympus America Inc. accounts for 67.7% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2023 at $14,251 and has fallen 99.3% since, to $98 in 2025.
Across 268 payments — averaging $69.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$13K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$707
- Redhill Biopharma Inc.$502
- Pfizer$395
- Ferring Pharmaceuticals Inc.$347
- plus $2K from 24 others
Across 8 payments — averaging $2641.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$21K
What the payments were for
- Food & beverage$6,06332%
- Other$12,69268%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 1 | $12,692 |
| AbbVie(2 entities) | 84 | $2,070 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 43 | $707 |
| Redhill Biopharma Inc. | 19 | $502 |
| Pfizer | 18 | $395 |
| Ferring Pharmaceuticals Inc. | 19 | $347 |
| E.r. Squibb & Sons, L.L.C. | 2 | $250 |
| Merck | 13 | $219 |
| Johnson & Johnson | 9 | $218 |
| Daiichi Sankyo Inc. | 8 | $160 |
| Capsovision, Inc. | 2 | $151 |
| Sanofi | 6 | $146 |
| Boston Scientific | 1 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $115 |
| Intercept Pharmaceuticals, Inc. | 5 | $100 |
| Bristol Myers Squibb | 5 | $78 |
| Braintree Laboratories, Inc. | 4 | $73 |
| Gilead | 5 | $72 |
| QOL Medical, LLC | 4 | $58 |
| Ardelyx, Inc. | 2 | $51 |
| Ironwood Pharmaceuticals, Inc | 2 | $41 |
| Alfasigma USA, Inc. | 2 | $35 |
| Lilly USA, LLC | 1 | $29 |
| Janssen Scientific Affairs, LLC | 1 | $20 |
| Concordia Pharmaceuticals Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Axonics, Inc. | 1 | $18 |
| Intra-sana Laboratories | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Shionogi Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVIS EXERA lll COLONOVIDEOSCOPE$12,692
- EVIS EXERA III GASTROINTESTINAL VIDEOSCOPE$12,692
- ZEPOSIA$250
- Rinvoq$249
- ZENPEP$136
- Skyrizi$125
- XELJANZ$120
- SYNERGY$119
- Talicia$118
How this compares
$18,755 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 29 | $30,354 |
| Dexlansoprazole DrDexlansoprazole | 29 | $11,782 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 89 | $4,907 |
| Esomeprazole Magnesium | 31 | $2,011 |
| Famotidine | 175 | $1,608 |
| Mesalamine ErMesalamine | 11 | $1,141 |
| Pantoprazole Sodium | 73 | $1,064 |
| Omeprazole | 160 | $900 |
| Lactulose | 41 | $876 |
| CholestyramineCholestyramine (With Sugar) | 14 | $479 |
| Sulfasalazine | 12 | $471 |
| Sucralfate | 11 | $451 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 33 | $416 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 23 | $388 |
| Lansoprazole | 19 | $182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,070 | $30,35429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in New Hyde Park
- Ian StorchNew Hyde Park$166K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.